Drug Profile

RG 7921

Alternative Names: RG-7921

Latest Information Update: 08 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Feb 2023 Discontinued - Phase-I for Wet age-related macular degeneration in Switzerland (unspecified route) as not listed on current company pipeline (Roche pipeline, February 2023)
08 Feb 2023 Phase-I clinical trials in Retinal vein occlusion in Switzerland (unspecified route) (Roche pipeline, February 2023)
19 Oct 2022 RG 7921 is still in phase-I trials in Wet age-related macular degeneration in Switzerland (Roche pipeline, October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com